Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Inventory (2016 - 2025)

Guided Therapeutics' Inventory history spans 15 years, with the latest figure at $448000.0 for Q4 2025.

  • On a quarterly basis, Inventory fell 29.23% to $448000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $448000.0, a 29.23% decrease, with the full-year FY2025 number at $448000.0, down 29.23% from a year prior.
  • Inventory hit $448000.0 in Q4 2025 for Guided Therapeutics, down from $583000.0 in the prior quarter.
  • Over the last five years, Inventory for GTHP hit a ceiling of $648000.0 in Q3 2023 and a floor of $448000.0 in Q4 2025.
  • Historically, Inventory has averaged $595550.0 across 5 years, with a median of $595500.0 in 2022.
  • Biggest five-year swings in Inventory: surged 1137.25% in 2021 and later decreased 29.23% in 2025.
  • Tracing GTHP's Inventory over 5 years: stood at $571000.0 in 2021, then decreased by 4.03% to $548000.0 in 2022, then rose by 15.33% to $632000.0 in 2023, then rose by 0.16% to $633000.0 in 2024, then decreased by 29.23% to $448000.0 in 2025.
  • Business Quant data shows Inventory for GTHP at $448000.0 in Q4 2025, $583000.0 in Q3 2025, and $595000.0 in Q2 2025.